为明确心肌病相关基因变异，研究人员对 40 例土耳其患者行临床外显子组测序（CES），发现MYBPC3变异最多。 心肌病是一种心肌细胞存在缺陷，进而导致心脏功能出现故障的病症。心肌病依据分子和（或）全身改变被分为三大类，且有多个亚型。该疾病的表现与 ...

Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201SOUTH ...

Tenaya Therapeutics, Inc. announced that it will present new data on its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific ...

Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data ...

Tenaya is advancing TN-201, an AAV9-based gene therapy for the potential treatment of MYBPC3-associated HCM, a condition caused by insufficient levels of myosin-binding protein C (MyBP-C).

With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy (HCM), the company and its platform is attracting significant partnering ...

(NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today ...

Tenaya Therapeutics, Inc. announced the initiation of dosing in Cohort 2 of its MyPEAK™-1 Phase 1b/2 clinical trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM).

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker ...